Skip to main content

Advertisement

Table 1 Rash rating scales used in this investigation

From: Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

Grade EGFR-Inhibitor induced rash scale CTCAE Assessment scale
0 No rash No rash
1 Isolated pustule or erythematous patch < 1 cm in diameter, on either face/head/neck or chest/back Macular or papular eruption or erythema without associated symptoms
2 More than one erythematous patch or erythema and telangiectasia on either face/head/neck or chest/back Macular or papular eruption or erythema with pruritus or other associated symptoms; localized desquamation or other lesions covering < 50% of body surface area
3 More than one pustule or papules on either face/head/neck or chest/back with no associated erythema or telangiectasia Severe, generalized erythroderma or macular, papular or vesicular eruption; desquamation covering ≥ 50% body surface area
4 Both erythema/telangiectasia and pustules/papules limited to either face/head/neck or chest/back Generalized exfoliative, ulcerative, or bullous dermatitis
5 Pustules or papules and erythema/telangiectasia present on both the face/head/neck region and the chest/back Death